Graphite Bio, Inc. (GRPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRPH Stock Price Chart Interactive Chart >
GRPH Price/Volume Stats
|Current price||$2.34||52-week high||$34.00|
|Prev. close||$2.26||52-week low||$2.07|
|Day high||$2.37||Avg. volume||424,284|
|50-day MA||$4.01||Dividend yield||N/A|
|200-day MA||$10.49||Market Cap||135.65M|
Graphite Bio, Inc. (GRPH) Company Bio
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Most Popular Stories View All
GRPH Latest News Stream
|Loading, please wait...|
GRPH Latest Social Stream
View Full GRPH Social Stream
Latest GRPH News From Around the Web
Below are the latest news stories about Graphite Bio Inc that investors may wish to consider to help them evaluate GRPH as an investment opportunity.
Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SOUTH SAN FRANCISCO, Calif., January 27, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced participation in the following upcoming investor conferences:
The new lease represents a significant expansion the company, which currently occupies less than 20,000 square feet in South San Francisco.
Graphite Bios (NASDAQ:GRPH) lock-up period is set to expire on Wednesday, December 22nd. Graphite Bio had issued 14,000,000 shares in its initial public offering on June 25th. The total size of the offering was $238,000,000 based on an initial share price of $17.00. After the expiration of the companys lock-up period, restrictions preventing major shareholders 
Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #ASH21--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today presented a trial-in-progress poster for the companys Phase 1/2 CEDAR trial for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD). The poster is being presented at the 63rd American As
GRPH Price Returns